Daiichi Sankyo commences real-world studies of Lixiana

Daiichi Sankyo has enrolled the first patient in two studies that will provide evidence of the real-world efficacy of its novel oral anticoagulant Lixiana.

The ETNA-AF-Europe and ETNA-VTE-Europe registries aim to collect a robust set of information on how once-daily Lixiana is being used in real-world settings, providing insight into safety and efficacy parameters, as well as other important data that can help to guide best use of the drug.

In Europe, the ETNA programme will be conducted across 12 countries and will collect data from up to 15,700 patients.

Dr Juan-Carlos Jaramillo, head of market access and medical affairs at Daiichi Sankyo Europe, said: "ETNA is an exciting opportunity to provide further information enabling healthcare systems to make best use of this important medicine."

Lixiana is licensed in Europe for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism.

The drug was launched in the UK last month and has received a recommendation from the National Institute for Health and Care Excellence.